The efficacy and safety of anti-CD20 antibody for the treatment of B-ALL: a systematic review and meta-analysis.

ABSTRACT: Several clinical trials with anti-CD20 antibodies have successfully treated Acute Lymphoblastic Leukemia. Nevertheless, systematic comparisons between different anti-CD20 antibody trials are rare, and a comprehensive evaluation of their efficacy and safety has yet to be performed. The purpose of this systematic review and meta-analysis was to assess the efficacy and safety of anti-CD20 antibodies in the treatment of acute lymphoblastic leukemia and to guide clinical decision-making regarding the use of anti-CD20 antibody therapy. According to the PRISMA guidelines, Embase, Cochrane Library, PubMed, Web of Science, and ClinicalTrials.gov were searched for clinical trials conducted up to November 1, 2024, for the evaluation of anti-CD20 antibodies (rituximab, obinutuzumab, and ofatumumab) an

SUBMITTER: Zhou X 

PROVIDER: S-EPMC12717365 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature